EyeBiotech
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (7)
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Started: 3/27/2026
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Started: 9/12/2025
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Started: 4/30/2026
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Started: 4/16/2025
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Started: 8/7/2024
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Started: 11/12/2024
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Started: 6/12/2023